Treatment Algorithms: Claims Data Analysis – Pediatric Attention-Deficit/Hyperactivity Disorder (US) | 2024
Attention-deficit/hyperactivity disorder (ADHD) is one of most common pediatric disorders and one that can continue into adulthood. For decades, pediatric ADHD has been treated primarily with psychostimulants. Today, numerous convenient, once-daily, long-acting psychostimulants in a variety of distinct formulations are available in the United States. However, psychostimulants are classified as controlled substances in the United States, and the potential for abuse with these agents is a concern. As a result, nonstimulant therapies (e.g., atomoxetine, guanfacine ER) have become key therapeutic alternatives, despite the lingering perception of their less-robust efficacy versus that of psychostimulants. Indeed, this perception has led to the continued strong presence of psychostimulants in the treatment algorithm for pediatric ADHD.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line oftherapy in newly diagnosed pediatric ADHD? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric ADHD?
- How have branded drugs (e.g., Qelbree, Xelstrym) been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of pediatric ADHD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of pediatric ADHD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Azurity Pharmaceuticals, Arbor Pharmaceuticals, Eli Lilly, Tris Pharma, Supernus Pharmaceuticals, Takeda Pharmaceuticals
Key drugs: Atomoxetine (Strattera, generics), Adzenys XR-ODT, Dyanavel XR, Evekeo ODT, guanfacine ER (Intuniv, generics), Jornay PM, lisdexamfetamine dimesylate (Vyvanse, generics), methylphenidate ER (Concerta, Ritalin LA, generics), mixed amphetamine salts (Adderall XR, generics), Qelbree, Quillichew ER, Xelstrym, Zenzedi
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
